Numinus has provided an update on its Compassionate Access Trial which will evaluate psilocybin-assisted psychotherapy for substance use disorders. The trial will initially involve 30 participants. Having gone through two rounds of external peer review, the protocol is now finalized. The study, which is now in pre-implementation, will be conducted in collaboration with the contract research…


Previous articleMINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
Next articlePT233 – JR Rahn of MindMed – LSD, ADHD, and Decriminalization